Viral infections as a cause of cancer (Review)

C. CARRILLO-INFANTE\textsuperscript{1,2}, G. ABBADESSA\textsuperscript{1,3}, L. BAGELLA\textsuperscript{1,2,4} and A. GIORDANO\textsuperscript{1,2}

\textsuperscript{1}Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA; \textsuperscript{2}Department of Human Pathology and Oncology, University of Siena; \textsuperscript{3}Oncology and Hematology Department, Istituto Clinico Humanitas, Rozzano (Mi); \textsuperscript{4}Department of Biomedical Sciences, Division of Biochemistry, University of Sassari, Italy

Received January 16, 2007; Accepted February 22, 2007

Abstract. In order to promote carcinogenesis multiple factors must be orchestrated. The alteration of the cellular genome after a carcinogenic exposure may result in malignancy if apoptosis is prevented and the immune surveillance fails to eliminate the transformed cell. Infectious agents may exert these properties and transform a host cell. Viruses associated with human cancer are known as ‘tumor viruses’. Most of them are capable of integrating into the host genome and have the ability to immortalize the target cell in order to allow their own replication. The infected cell expresses the viral genes, which are able to induce cell growth, proliferation and prevent apoptosis. This review focuses on Epstein-Barr virus, human papilloma virus, hepatitis C virus, hepatitis B virus, human herpes virus 8 and human T-cell leukemia virus, since they have been already established as causative agents of human cancer. An understanding of the viral replication mechanism may provide new targets for the development of specified viral therapy that may have an impact not only on viral infections but in human cancer as well.

Contents

1. Introduction
2. General aspects of viral oncogenesis
3. Human papilloma virus (HPV)
4. Hepatitis B virus (HBV) and hepatitis C virus (HCV)
5. Human herpes virus 8 (HHV-8)
6. Human T-cell leukemia virus type-1 (HTLV-1)
7. Conclusion

Correspondence to: Dr Antonio Giordano, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, BioLife Science Bldg., Suite 333, 1900 N 12th Street, Philadelphia, PA 19122, USA
E-mail: giordano@temple.edu

Key words: tumor virus, cancer, oncogene, Epstein-Barr virus, human papilloma virus, hepatitis C virus, hepatitis B virus, human herpes virus 8, human T-cell leukemia virus

1. Introduction

Cancer is the final result of a number of genetic alterations occurring in a cell. These changes may alter the balance between proliferation and programmed cell death (apoptosis) mechanisms and transform the cell. Malignant transformation is divided into stages of initiation, promotion and progression (Fig. 1). Usually, there is a long latent period from the moment of carcinogenic exposure to the neoplastic transformation in which the somatic cell is allowed to proliferate while accumulating multiple genetic mutations that might lead to a disease in an individual. Inherited genetic alterations can occur in somatic and in gonadic cells, allowing their presence in future generations (1,2). Multiple factors have been associated with the oncogenic process such as environment, lifestyle, host factors, infectious agents and inheritance. Understanding cancer etiology and risk factors is a useful tool to help identify high-risk populations, and improve screening procedures and preventive methods.

Among these risk factors, infectious agents may be one important preventable cause of cancer. Within this group, viruses are the most common agents involved in the pathogenesis of human cancer. In the past decades, viruses have played an important role in cancer biology, contributing significantly in our comprehension of cell signaling and growth control pathways that result in cancer. This insight has been achieved through the study of viral transforming properties. Consequently, viruses have been suggested as causative agents of human neoplasia. Recent estimates have shown that 17.8% of cancer cases are attributable to infectious agents and of these, 12.1% correspond to viral infections (Table I) (3).

2. General aspects of viral oncogenesis

Once a viral infection has been established, innate and adaptive immunity are activated in response, aimed to eliminate the infection. An acute inflammation is a short process that is usually protective for the host with the purpose of eliminating the pathogen. Chronic inflammation may result from an unresolved acute inflammation, due to failure in eradicating the pathogenic agent. Therefore, chronic inflammation may favor the persistence of the pathogen in the tissue for a prolonged period of time (4,5). The infection itself usually is not enough
to create the proper environment for cancer formation. Factors such as host immunity and chronic inflammation play an important role in promoting the conditions for neoplastic cells to proliferate. In fact, chronic inflammation is supposed to be beneficial for the host by trying to clear the antigenic insult, but it has also been recognized as a factor that can promote carcinogenesis. A variety of inflammatory cells are activated during this process, releasing cytokines, chemokines and nitric oxide (NO) particularly, an inducible isoform of nitric oxide synthase (iNOS), and NO-derived reactive nitrogen species (RNS), which may be able to cause DNA damage and have a direct effect upon cell proliferation and neoangiogenesis (6-8).

Some viruses have the capacity to elude the immune system and remain latent. One way for them to achieve this objective is by inducing the regulatory T cells (Tregs), which physiologically cause immunosuppression to protect the host from a hyperactive immune response secondary to a chronic infection/inflammation (9-11). These events might leave the host susceptible to either permit a virus to remain latent or to reactivate a latent infection (12). The mechanism to remain latent in the host depends on the type of virus. DNA tumor viruses such as HPV, EBV, HBV and Kaposi sarcoma herpes virus (KSHV) usually persist by either integrating in the host genome or by remaining episomally. RNA tumor viruses such as human T-cell leukemia virus type 1 (HTLV-1) and HIV are reversely transcribed into a double-stranded DNA, with a further integration into the chromosomal DNA (Fig. 2) (13). HIV has been indirectly associated with carcinogenesis; it induces a chronic state of immunosuppression, reducing immunosurveillance for neoplastic cells and increasing the risk of reactivation of latent viruses as well as the risk of acquiring new infections (14,15). HCV is an RNA tumor virus which, in contrast with HTLV-1 and HIV, lacks the capacity to integrate into the host genome. As a consequence, HCV exerts its carcinogenic influence by damaging liver tissue through chronic inflammation. Tumor viruses may directly transform the cell by carrying oncogenes into a cell or by activating cellular proto-oncogenes. These viral-derived oncogenes can potentially interfere with normal cell function by producing transforming growth factors that deregulate growth control and proliferation, leading to malignant transformation.

Table I. Infectious agent-associated malignancy.

<table>
<thead>
<tr>
<th>Viral agent</th>
<th>Route of infection</th>
<th>Human cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBV</td>
<td>Saliva</td>
<td>BL, NPC, NHL, PTD</td>
</tr>
<tr>
<td>HPV</td>
<td>Sexual</td>
<td>Cervical cancer</td>
</tr>
<tr>
<td>HCV</td>
<td>Sexual/post-transfusion/ IV drug-user</td>
<td>Hepatocarcinoma</td>
</tr>
<tr>
<td>HBV</td>
<td>Perinatal/sexual</td>
<td>Hepatocarcinoma</td>
</tr>
<tr>
<td>HHV-8</td>
<td>Sexual</td>
<td>Kaposi’s sarcoma</td>
</tr>
<tr>
<td>HTLV-1</td>
<td>Sexual/perinatal/ parenteral</td>
<td>ATL, HAM</td>
</tr>
</tbody>
</table>

EBV, Epstein-Barr virus; HPV, human papillomavirus; HCV, hepatitis C virus; HBV, hepatitis B virus; HHV-8, human herpes virus 8; HTLV-1, human T-cell leukemia virus type-1; BL, Burkitt’s lymphoma; NPC, nasopharyngeal carcinoma; NHL, non-Hodgkin’s lymphoma; PTD, post-transplant-disease; ATL, adult T-cell leukemia; HAM, progressive myelopathy.

---

**Figure 1.** Sequence of events of infection/inflammation and cancer. Acute inflammation occurs, as the host’s first response to eliminate an infection. Unresolved infection may result in chronic inflammation. Inflammation generates the production of iNOS and RNS, which are potent DNA-damaging agents causing genome mutations and instability. Chronic inflammation contributes to apoptosis and tissue generation with the promotion of microvessel formation and cell proliferation. This sequence of events corresponds to the stages of initiation, promotion and progression for cancer development.
DNA tumor viruses, in particular, carry oncogenes that target cellular tumor suppressor proteins such as p53 and pRb (retinoblastoma gene product), and are essential for viral replication and cellular transformation (18). All of these events might cause cell transformation, which may not necessarily mean cancer until a dysfunctional immune surveillance system is unable to prevent or modulate tumor development. This condition has been observed in individuals with chronic states of immunosuppression, such as patients receiving treatment to prevent allograft rejection, those with acquired immunodeficiency (AIDS) and individuals with congenital immune disorders, which generally are at a higher risk of developing cancer (19,20).

Different guidelines have been proposed in order to establish the relationship between infectious agents and diseases (Tables II and III). The agents considered in this review are EBV, HPV, HBV, HCV, KSHV and HTLV-1, which through epidemiological studies and molecular biology analysis have been established as causative agents of cancer.

2. Epstein-Barr virus (EBV)

EBV is a ubiquitous double-stranded DNA human virus of the gammaherpesviridae subfamily. It infects approximately 95% of the population worldwide with a primary asymptomatic infection occurring within the first three years of life. When primary infection is delayed until adolescence or adulthood, it presents as infectious mononucleosis (23). After the primary infection, individuals remain as asymptomatic carriers. EBV is etiologically linked to Burkitt’s lymphoma (BL), which is a tumor with higher incidence in areas with endemic malaria and is associated with nasopharyngeal carcinoma (NPC), which has a higher incidence among salted fish consumers. EBV also causes...
LMP-1 is a viral oncogene that resembles a cell-surface receptor. It prevents EBV-infected cells from apoptosis by the induction of anti-apoptotic proteins such as BCL-2, A20 and MCL-1 (30,35,36). LMP1 activates the NF-κB transcription factor in B-lymphocytes and modulates epidermal growth factor receptor in epithelial cells (37,38). LMP-1 is also implicated in three other signaling pathways, c-Jun N-terminal kinase (JNK)-AP-1, mitogen activated protein kinase (p38/MAPK) and Janus kinase (JAK)-STAT, which regulate cell proliferation and apoptosis (39,40). The role of EBNA3A, EBNA3B and EBNA3C is to regulate the expression of LMP-1. From this group of proteins, EBNA3C has shown to be essential in promoting immortalization of B-lymphocytes in presence of EBNA2 (41). EBNA-LP function allows the cell to re-enter the cell cycle by stimulating the activation of cyclin D2 (42). The expression of these genes varies according to the malignancy. In Burkitt's lymphoma and in post-transplant lymphoproliferative disease, EBNA1 and EBERs are expressed, while EBNA1, EBERs, LMP1 and LMP2 are expressed in Hodgkin's disease and NPC (43). This difference in gene expression is useful to understand the molecular aspects of each condition.

### 3. Human papilloma virus (HPV)

HPV is a small non-enveloped double-stranded DNA tumor virus. It causes a diverse range of epithelial lesions that transform from benign lesions such as anogenital warts, mild cervical dysplasia and recurrent respiratory papillomatosis, to pre-malignant and malignant lesions. Over 100 different types of HPV have been identified, but only some strains have demonstrated sufficient evidence to be designated as definitive human carcinogens. These strains are HPV-16 and HPV-18, which are considered ‘high-risk’ types. HPV-16 and HPV-18 account for approximately 70% of cervical and anal cancers worldwide. ‘Low-risk’ types are HPV-6 and HPV-11, accounting for approximately 90% of genital warts (44-48). HPV infects actively well-differentiated keratinocytes at the basal epithelial layer of the stratified squamous epithelium. It integrates into the host genome randomly and encodes for six non-structural viral regulatory proteins (E1, E2, E4, E5, E6 and E7) from the early region of the viral genome and two structural viral capsid proteins (L1 and L2) from the late region. The DNA integration process is preceded by the disruption of the E1/E2 regions, with the further deletion of the E2 region.

The DNA integration process is preceded by the disruption of the E1/E2 regions, with the further deletion of the E2 region. The etiologic role of HPV upon cervical cancer has been well established. Strategies to prevent HPV and cervical cancer
have been relying on prompt diagnosis and treatment. Recently, the quadrivalent and bivalent vaccines have been approved by the FDA. They are recombinant vaccines made of virus-like-particles (VLPs) derived from the L1 capsid protein of HPV types 6, 11, 16 and 18 for the quadrivalent vaccine; 16 and 18 for the bivalent vaccine respectively. They mimic the HPV virus, although they lack the viral DNA content (58,59). These HPV vaccines are expected to have a significant impact on HPV infection and cervical cancer incidence in the future.

4. Hepatitis B virus (HBV) and hepatitis C virus (HCV)

HBV and HCV are hepatotropic viruses that can cause both acute and chronic hepatic infections. Once these viruses bypass the immune response they may establish a chronic active hepatitis, which is known to be a major risk factor for developing hepatocellular carcinoma (HCC) in humans (60). These hepatotropic viruses are responsible for 80-90% of HCC cases worldwide. HCC arises most frequently in HBV- and HCV-induced cirrhotic livers, being most commonly associated with alcohol use in HCV infection (61). HBV infections in adults are usually cleared. In contrast, when HBV infection occurs early in life, it tends to become persistent (62,63). These liver-tropic viruses have different biological properties; nevertheless, they share pathogenic mechanisms of chronic infection induction.

HBV is a small circular double-stranded DNA, which shares with the retroviruses the reverse transcription system. It may integrate into the cellular DNA, at random sites. When HBV-DNA integrates, it may target genes involved in cellular signaling pathways as sites of viral integration, such as the hTERT pathway (64,65). HBV DNA has also been found integrated next to v-erb-A which is an oncogene expressed inappropriately in HCC-cases (66). HBV DNA integration may cause chromosomal deletions, as found at the chromosomal region 17p11.2-12 causing the loss of the p53 gene (67). HBV DNA integration may cause disruptions or translocations, resulting in genetic instability (68,69). The HBV genome has itself some oncogenic activities, expressing from integrated HBV the X gene (HBx), which seems to contribute indirectly to carcinogenesis by activating pathways such as mitogen-activated protein kinase (MAPK), c-jun N-terminal kinase (JNK), protein kinase C (PKC), phosphatidylinositol 3-kinase (PI 3-kinase), protein kinase B (PKB/Akt) and JAK/STAT signaling cascades (70,73). It disrupts p53 pathway and alters the expression level of the retinoblastoma gene (Rb), affecting cell cycle progression (74). HBx is not considered a direct transforming gene and therefore, the tumor induction mechanism of HBV is believed to be indirect.

HCV is a single-stranded RNA virus related to the fla-viviridae family. It has been recognized as a post-transfusion transmitted cause of hepatitis and in recent years among injecting-drug users (75). HCV has a marked genetic variability given by its mixed population of heterogeneous HCV-RNA molecules designated quasispecies, which provide HCV with many immunological variants that permit the virus to escape the host immunity and persist as a chronic liver infection (76,77). Studies have been made in order to determine the oncogenic properties of HCV in liver cells. An in vitro study has shown that HCV exerts its influence upon cell progression through the phosphorylation of RNA-regulated serine/threonine protein kinase (PKR), deregulating G2/M phase and serving as a pathway for HCV to evade the antiviral effect of interferons (INFs) (78). HCV lacks the capacity to integrate itself into the host genome and does not carry oncogenes. Instead, it possesses an indirect mechanism of carcinogenesis based on chronic liver damage, inflammation and cellular regeneration.

5. Human herpes virus 8 (HHV-8)

Human herpes virus 8 (HHV-8), also referred to as Kaposi’s sarcoma-associated herpes virus (KHSV), is a double-stranded DNA virus classified in the Rhadinovirus genus, which belongs to the γ2 herpesviridae sub-family. KHSV/HHV-8 is the etiological cause of Kaposi’s sarcoma (KS). It is sexually transmitted remaining latent with the possibility of reactivation in immunocompromised individuals. KHSV/HHV-8 is a multifocal angioproliferative disease, commonly manifested as a cutaneous lesion. It is also associated with other proliferative disorders such as primary effusion lymphoma (PEL), and multicentric Castleman’s disease (MCD) (79-81). There are four major forms of KS: the first type is the classic form, which is present in Mediterranean individuals. The second form consists in the association between KS and AIDS, where patients commonly present with disseminated KS. The third form is the endemic type and the fourth is the iatrogenic type, which occurs in individuals receiving immunosuppressive therapy (82). KHSV/HHV-8 establishes latent infection in the host, persisting episomally in B-lymphocytes. KSHV has a latent and a lytic phase. During the latent phase, it evades the immune system, persisting in the host cell having a restricted expression of genes (83). During lytic replication, viral proteins are produced unrestrictedly. KSHV produces a variety of immunomodulatory proteins with paracrine properties (84). KSHV contains several gene products with transforming properties among the most important are the viral G-protein coupled receptor (vGPCR), which is an IL-8 receptor analog and vIL-6, which modulates cell growth. The K1 protein can induce VEGF expression, while the v-cyclin and v-Bcl-2 proteins may inhibit apoptosis. They activate pathways controlling cellular growth, angiogenesis and inhibition of apoptosis such as the PI3K MAPK family Jak/STAT and nuclear factor-xB (NF-xB) signaling pathway (85,86). These proteins have shown transforming properties in vitro and in transgenic mice. However, HKSV gene products transforming properties still remain to be fully elucidated (87).

6. Human T-cell leukemia virus type-1 (HTLV-1)

HTLV-1 was the first human retrovirus described to be associated with malignancy (88). HTLV-1 is a T-cell tropic virus, which after infection promotes T-cell activation and proliferation (89). It causes adult T-cell leukemia (ATL) and progressive myelopathy (HAM). The transmission of HTLV-1 occurs through sexual contact and mother-to-infant infection (90). HTLV-1 is a single-stranded RNA virus that contains retroviral genes encoding for the core proteins (gag), reverse transcriptase (pol), surface glycoprotein for receptor binding (env) and transcriptional activator (tax) genes (91). After
infection it is reversely transcribed into a double-stranded DNA using genomic RNA as a template; subsequently, it is integrated randomly into the host chromosome without producing insertional mutagenesis. HTLV-1 contains a unique integrated randomly into the host chromosome without proviruses. This work has been funded by NIH, Sbarro Health Research Organization (SHRO), www.shro.org and Within3-Prometeonetwork www.within3.com, www.prometeonetwork.com.

References


Acknowledgements

The authors thank Professor Alessandra Renieri from the University of Siena, Dr Gaetano Romano and Ms. Marie Basso for their precious comments and advice in the preparation of the manuscript.
42. Cheng G and Baltimore D: TANK, a co-inducer with TRAF2 of


